Kanabo set to launch world’s first cannabis vape trial

Medical cannabis company, Kanabo, has applied to undertake the world’s first clinical trial for a cannabis vape pen. 

The company has applied for approval of what is thought to be the first clinical trial for a cannabis vape pen in the world, on its recently-launched VapePod device.

It is hoped that the three-month trial will provide bioavailability and efficacy data for Kanabo’s proprietary cannabis inhalation formulas, used in conjunction with the VapePod. 

The VapePod, a medical grade, handheld vaporiser which enables accurate and precise dosing of cannabis extract, was rolled out to UK patients earlier this year.  

Kanabo, in partnership with Seach Medical Group, has submitted a clinical trial protocol for approval at the Hadassah Medical Centre and subsequent review by the Helsinki Committee, to test the impact from the inhalation of various cannabis formulas via its proprietary VapePod delivery device, which dispenses standardised and metered inhalations, on healthy volunteers.

Kanabo’s VapePod device

As part of the trial, participants will undertake a pharmacokinetic analysis to define THC and CBD absorption, distribution, metabolism and excretion, following the administration of the VapePod formulas. 

Once successfully completed, the trial is expected to help Kanabo target the segments of the medicinal cannabis market, for patients who wish to manage their pain using a clean and measurable method of treatment.

The outcome of the trial will see the company gain approval to sell the medical vape and formulas in Israel, the first cannabis vape cartridges in the Israeli market, as well as supporting sales in the UK and Germany by providing physicians and the medical establishments with evidence-based medicine.

Avihu Tamir, Kanabo’s CEO, commented: “This is a ground-breaking trial which will evaluate the bioavailability and efficacy of Cannabis-based inhalation formulas administered via Kanabo’s VapePod medical device. It is an important milestone as it will help us with our ongoing efforts to allow specialist consultants to prescribe a metered dose of medicinal cannabis that is healthier for patients than the alternative which is typically smoking.”